Multiple Myeloma

Bone progression in multiple myeloma: Benefit of zoledronic acid for patients achieving at least Very Good Partial Response and prognostic value of bone turnover markers

The Lancet

The Asco Post

Off-the-shelf CAR T-cell therapy produces deep, durable responses in heavily pretreated multiple myeloma

Journal of Translational Medicine

Long-term follow-up results of anti-BCMA CAR-T cell therapy combined with autologous hematopoietic stem cell transplantation in relapsed/refractory multiple myeloma with extramedullary disease

Transplantation and Cellular Therapy

Trial in progress: QUINTESSENTIAL-2—a phase 3 Study of arlocabtagene autoleucel versus standard of care in adult patients with relapsed and refractory multiple myeloma (RRMM) exposed to lenalidomide

The FEBS Journal

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

Cancer Medicine

Lenalidomide plus dexamethasone as first-line therapy in transplant-ineligible patients with multiple myeloma

American Journal of Hematology

The role of bispecific antibodies in relapsed/refractory multiple myeloma with renal impairment: A systematic review

Blood Advances

BCMA/CD19 dual-targeting CAR T cell therapy in older patients with newly diagnosed multiple myeloma: A phase I study

BMC Infectious Diseases

Machine learning triumphs in differentiating fungal and bacterial infections

Frontiers in Oncology

Morphology-based cytogenetic risk prediction in multiple myeloma from bone marrow smears

International Journal of Hematology

Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: a systematic review and meta-analysis

Frontiers in Digital Health

Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic

Cancer Control

The changing landscape of second primary malignancies in multiple myeloma: A SEER population-based study between two therapeutic eras

Journal of Clinical and Experimental Hematopathology

Pseudoprogression of extramedullary lesions during elranatamab therapy in relapsed or refractory multiple myeloma

Frontiers in Oncology

Ocular toxicities of targeted therapies and immunotherapies in hematologic malignancies

Molecular Therapy

CAR-modified marrow infiltrating lymphocytes efficiently target malignant plasma cells with very low antigen density

Frontiers in Immunology

Tailored strategies for improved control of CAR-T cells in multiple myeloma

Clinical Lymphoma, Myeloma & Leukemia

MRD directed consolidation in multiple myeloma-Are we there yet?

American Journal of Therapeutics

Global clinical trial landscape of chimeric antigen receptor T-cell therapy for multiple myeloma: Current status and future trends

EClinicalMedicine

Temporal trends in progression risk in smoldering myeloma: A systematic review

Annals of Hematology

Daratumumab-based first-line therapy benefit multiple myeloma patients in a real-world setting: a multi-center retrospective propensity score-match study

Blood Reviews

Redefining central nervous system multiple myeloma: From rare phenomenon to emerging entity

European Journal of Haematology

Prognostic impact of the Hevylite Assay in patients with IgG or IgA multiple myeloma treated within the GMMG-MM5 trial

Clinical and Experimental Medicine

Clinical outcomes and safety of CD47-targeted immunotherapies across hematologic malignancies: A systematic review of monoclonal antibodies and fusion proteins in combination strategies

Cell Communication and Signaling

CAR-NK cell therapy in multiple myeloma: From preclinical and clinical landscape to joining the force for treatment strategies optimization

BMC Pulmonary Medicine

Evaluating pre-transplant nutritional indices as predictors of pneumonia and mortality in multiple myeloma patients post-autologous stem cell transplantation

Leukemia & Lymphoma

Treatment response assessment using whole body diffusion weighted-magnetic resonance imaging in myeloma: A retrospective cohort study

Frontiers in Oncology

Post-progression outcomes following BCMA-directed CAR T-cell therapy in myeloma: Impact of extramedullary and paramedullary disease

Supportive Care in Cancer

Symptom distress and fear of progression associated with quality of life in multiple myeloma patients receiving treatment

Cureus

Dural-based plasmacytoma presenting as the initial sign of multiple myeloma

HemaSphere

Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN-HARMONY Alliance platform

Advances in Hematology

Newly diagnosed high-risk multiple myeloma: Outcomes and management

European Journal of Haematology

From trials to practice: A 2025 review of idecabtagene vicleucel and ciltacabtagene autoleucel efficacy across clinical studies and real-world evidence

The Journal of the American Academy of Orthopaedic Surgeons

Influence of chimeric antigen receptor T-cell therapy on fracture risk of patients with multiple myeloma

Discover Oncology

Deciphering and targeting oncogenic pathways through integrated approaches and amino acid metabolism in hematologic malignancies

Nature Reviews. Clinical Oncology

EHA-EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma

Cancer Nursing

Dynamic changes in symptom clusters and symptom networks in patients with multiple myeloma: Across-lagged network analysis

HemaSphere

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet-treated multiple myeloma without transplant

International Journal of Molecular Sciences

Breaking barriers: The role of the bone marrow microenvironment in multiple myeloma progression

Future Oncology

Community hematologist/oncologist perspectives on minimal residual disease testing in patients with multiple myeloma

Clinical Lymphoma, Myeloma & Leukemia

Practical guidance on the clinical management of belantamab mafodotin for patients with relapsed/refractory multiple myeloma: Recommendations from the Middle East and North Africa expert panel

ASCO 2025

DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone vs pomalidomide plus bortezomib and dexamethasone in relapsed/refractory multiple myeloma: A subgroup analysis in patients with high-risk cytogenetic features

Frontiers in Oncology

Subcutaneous administration of isatuximab in patients with multiple myeloma by an on-body delivery system: Results of a nurse survey

Blood

Are we ready for an MRD-driven approach in multiple myeloma?

Nature Cancer

ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

Current Obesity Reports

Unraveling obesity and multiple myeloma: Insights from epidemiology and molecular mechanisms

Blood and Lymphatic Cancer

An updated indirect comparison of elranatamab versus a real-world external control arm in triple-class refractory multiple myeloma

The New England Journal of Medicine

Daratumumab or active monitoring for high-risk smoldering multiple myeloma

Journal of Clinical Oncology

Isatuximab subcutaneous by on-body delivery system vs isatuximab intravenous plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Phase 3 IRAKLIA study

Targeted Oncology

Teclistamab dosing in responders: Modeling and simulation results from the MajesTEC-1 study in relapsed/refractory multiple myeloma

Patient Preference and Adherence

Perspectives of healthcare providers and patients with relapsed/refractory multiple myeloma on treatment priorities and novel therapies

Bone Marrow Transplantation

Attitudes and perspectives of oncologists about measurable residual disease testing in multiple myeloma: Initiative for standardizing guidelines

Blood Cancer Journal

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: A multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

Cancer Reports

Efficacy and safety of quadruplet therapy in newly diagnosed transplant-eligible multiple myeloma: A systematic review and meta-analysis

Clinical Lymphoma, Myeloma & Leukemia

Expert perspectives on current challenges and emerging approaches for multiple myeloma: Narrative review of an inaugural bridging the gaps in leukemia, lymphoma, and multiple myeloma

Open Forum Infectious Diseases

Outcomes and risk factors for influenza and respiratory syncytial virus lower respiratory tract infections and mortality in patients with lymphoma or multiple myeloma: A 7-year retrospective cohort study

JCO Precision Oncology

Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors

Cancer Medicine

Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review

Mediterranean Journal of Hematology and Infectious Diseases

How first-line therapy is changing in non-transplant eligible multiple myeloma patients

The Lancet Haematology

Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study

Cancer Medicine

Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma

Transfusion Clinique et Biologique

Impact of quadruplet induction therapy on stem cell mobilization yields in newly diagnosed multiple myeloma

Clinical Pharmacology and Therapeutics

A novel two-part mixture model for the incidence and time course of cytokine release syndrome after elranatamab dosing in multiple myeloma patients

European Journal of Haematology

Completion of distress screening and correlates of distress score in patients with multiple myeloma at initial evaluation at a transplant center

Iranian Journal of Medical Sciences

Advancing multiple myeloma immunotherapy: A review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment

Presse Medicale

Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma

Clinical Cancer Research

Population pharmacokinetics of orvacabtagene autoleucel, an autologous BCMA-directed chimeric antigen receptor T-cell product, in patients with relapsed/refractory multiple myeloma

Leukemia & Lymphoma

Are we maintaining minimal residual disease in myeloma?

Blood and Lymphatic Cancer: Targets and Therapy

The antibody drug conjugate, belantamab-mafodotin, in the treatment of multiple myeloma: A comprehensive review

Journal of Cancer Policy

Financial conflicts among physician speakers at the April 12, 2024, Oncology Drug Advisory Meeting: Who decided that MRD can be a novel regulatory endpoint in myeloma?

Cancer Metastasis Reviews

CAR T-cell therapy to treat multiple myeloma: Current state and future directions

Blood Advances

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma

Journal of Patient-Reported Outcomes

Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma

Annals of Hematology

Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

Clinical Lymphoma, Myeloma & Leukemia

Real world outcome of high-risk multiple myeloma: An Indian tertiary care centre experience

Pharmaceuticals

Unravelling transplant-ineligible newly diagnosed multiple myeloma treatment in real-world practice in Spain: The CARINAE study

Cancer Medicine

Comparison of time to next treatment or death between front-line daratumumab, lenalidomide, and dexamethasone (DRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) among transplant-ineligible patients with multiple myeloma

European Journal of Haematology

Real-world evidence on prognostic value of MRD in multiple myeloma using flow cytometry

Leukemia

LocoMMotion: A study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)

Scientific Reports

Liquid biopsy of peripheral blood using mass spectrometry detects primary extramedullary disease in multiple myeloma patients

Blood

Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

The Oncologist

Evaluating early intervention in smoldering myeloma clinical trials: A systematic review

PharmacoEconomics

Healthcare resource utilization and associated costs during the first 5 years after diagnosis and at the end of life: A nationwide cohort study of patients with multiple myeloma in Finland

Frontiers in Immunology

Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

Clinical Lymphoma, Myeloma & Leukemia

Pomalidomide/daratumumab/dexamethasone in relapsed or refractory multiple myeloma: Final overall survival from MM-014

NPJ Digital Medicine

Joint AI-driven event prediction and longitudinal modeling in newly diagnosed and relapsed multiple myeloma

Journal of Blood Medicine

Secondary polycythemia may be an early clinical manifestation of multiple myeloma: A case report

Frontiers in Oncology

Advancements in microenvironment-based therapies: Transforming the landscape of multiple myeloma treatment

Japanese Journal of Radiology

Review of whole-body magnetic resonance imaging in multiple myeloma

The Oncologist

Physical activity and exercise motivation of multiple myeloma patients: a prospective cross-sectional study

Cancer Immunology, Immunotherapy

The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients

European Journal of Haematology

A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapies

Journal of Clinical Oncology

Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)

Cancer Science

The impact of daratumumab pretreatment on multiple myeloma patients undergoing autologous transplantation

Blood

Financial toxicity and time toxicity in multiple myeloma: Prevalence, predictors, and impact on QOL

Oncology

Cardiac adverse events associated with multiple myeloma patients treated with proteasome inhibitors

New England Journal of Medicine

Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

JAMA Network Open

Patient-reported adverse events and early treatment discontinuation among patients with multiple myeloma

Nature Reviews Clinical Oncology

Long-term outcomes following CAR T cell therapy: What we know so far

Blood Cancer Journal

Addressing the disparities: The approach to the African American patient with multiple myeloma

Journal of Neurosurgery

CyberKnife stereotactic radiosurgery for extramedullary plasmacytoma in the external auditory canal: illustrative case

CancerNetwork

Bispecific antibody dose schedules in relapsed/refractory multiple myeloma

Cancers (Basel)

The impact of outpatient versus inpatient administration of CAR-T therapies on clinical, economic, and humanistic outcomes in patients with hematological cancer: A systematic literature review

HemaSphere

P940: An outpatient model for teclistamab step-up dosing administration – Initial experiences at Fox Chase Cancer Center BMT program

The New England Journal of Medicine

Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma

VJHemOnc – Video Journal of Hematology & HemOnc

iStopMM: The psychological effects of MGUS screening and changes to clinical presentation of myeloma

Annals of Hematology

Reporting of adverse events of treatment interventions in multiple myeloma: An overview of systematic reviews

Blood

Establishment of a clinical pharmacist-led multiple myeloma clinic with collaborative prescribing model at the National Center for Cancer Care and Research in Qatar

Scientific Reports

Association of proton pump inhibitor use with survival and adverse effects outcomes in patients with multiple myeloma: Pooled analysis of three clinical trials

StatPearls

Relapsed and refractory multiple myeloma

Current Oncology

Relapsed/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse

Journal of Hematology & Oncology

The association of Agent Orange exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: A population-based study of Vietnam War era veterans

Blood Advances (2024) 8 (1): 236–247.

Prevalence and impact of diabetes on survival of patients with multiple myeloma in different racial groups

Blood (2023) 142 (Supplement 1): 4705

Real-world outcomes for relapsed or refractory multiple myeloma patients treated with lenalidomide and daratumumab sparing triplet regimens: a United States retrospective cohort study

Blood (2023) 142 (Supplement 1): 4693

Cell-free DNA from blood or bone marrow as alternatives to bone marrow cells for molecular diagnostics and monitoring of multiple myeloma

Leukemia

Cellular dynamics following CAR T cell therapy are associated with response and toxicity in relapsed/refractory myeloma

Indian Journal of Cancer

Second stem cell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem cell transplant: A 15-year retrospective institutional analysis

Cureus

Explosive disease progression after single-agent b-cell maturation antigen-targeted treatment in multiple myeloma: A report of three cases in Sheikh Shakhbout Medical City

The Lancet. Haematology

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial

Journal of Chemotherapy

Varicella zoster virus reactivation reported with isatuximab use

European Journal of Haematology

Treatment sequences and drug costs from diagnosis to death in multiple myeloma

Platelets

Multiple myeloma and its treatment contribute to increased platelet reactivity

Cancer Discovery

CAR T-cell availability for multiple myeloma improving but still limited

Journal of the Advanced Practitioner in Oncology

Patient-reported outcomes with belantamab mafodotin treatment in patients with triple-class refractory multiple myeloma

Cancers (Basel)

Bispecific antibodies in multiple myeloma: Opportunities to enhance efficacy and improve safety

ASCO Daily News

Bispecific antibodies in refractory multiple myeloma: Basics and unanswered questions

Current Oncology

Relapsed/refractory multiple myeloma: A review of available therapies and clinical scenarios encountered in myeloma relapse

PR Newswire

U.S. FDA approves TALVEY™ (talquetamab-tgvs), a first-in-class bispecific therapy for the treatment of patients with heavily pretreated multiple myeloma

Blood Cancer Journal

Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study

Leukemia and Lymphoma

Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: A population-based study

U.S. Food & Drug Administration

FDA grants accelerated approval to elranatamab-bcmm for multiple myeloma

ASCO 2023

First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)

Blood

Increased COVID-19 breakthrough infection risk after SARS-CoV-2 vaccine boosting in patients with plasma cell disorders: A large nationwide Veterans Affairs study

Blood

Final results from the first-in-human phase 1/2 study of modakafusp alfa, an immune-targeting attenuated cytokine, in patients (Pts) with relapsed/refractory multiple myeloma (RRMM)

The Lancet

SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of ‘biomarker-defined early multiple myeloma’—a systematic review with meta-analysis

Nature

Dietary and microbiome evidence in multiple myeloma and other plasma cell disorders

Transplantation and Cellular Therapy

Ethical challenges in CAR-T slot allocations